First-in-human positron emission tomography study of intranasal insulin in aging and MCI.

ABSTRACT:

Introduction

Intranasal insulin (INI) is being explored to treat Alzheimer's disease and other conditions. The method of intranasal delivery has been shown to affect outcomes, requiring validation prior to clinical investigation. We conducted a first-in-human positron emission tomography (PET) study using a novel radiotracer, [⁶⁸Ga]Ga-NOTA-insulin, administered intranasally with a specialized device (Aptar Cartridge Pump System) to evaluate the kinetics of insulin uptake and distribution in the brain.

Methods

[⁶⁸Ga]Ga-NOTA-insulin was intranasally administered (≈ 0.037 ± 0.001 GBq) to adults who were cognitively normal (CN, n = 7) or had mild cognitive impairment (MCI, n = 9). A dynamic 40 minute brain PET scan, followed by a 15 minute who

SUBMITTER: Sai KKS 

PROVIDER: S-EPMC12284729 | biostudies-literature | 2025 Jul-Sep

REPOSITORIES: biostudies-literature